Comparative Efficacy of Myo-Inositol and Metformin in Polycystic Ovary Syndrome Management: A Randomized Controlled Trial in a Local Setting

Abstract

INTRODUCTION

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy in reproductive-aged women, mainly characterized by oligoanovulation (oligomenorrhea) and hyperandrogenism. Insulin resistance represents a major pathophysiological feature of the syndrome and, therefore, insulin-sensitizing agents (metformin and thiazolidinediones) have been applied in PCOS women. So we want to conduct this study to find the more efficacious drug in resolution of PCOS through decrease in LH/FSH in local setting.

OBJECTIVES

To compare the mean LH/FSH ratio with myo-inositol versus metformin for management of females with polycystic ovarian syndrome.

SUBJECTS AND METHODS

100 patients of PCOS (Polycystic ovarian syndrome) meeting the inclusion criteria were included in the study. The patients were randomly allocated in two groups by lottery method. Patients in Group A were started upon metformin therapy and group B on myoinositol. All the patients were assessed for efficacy both the drugs. Data was collected on proforma and analyzed in SPSS version 10.0. P-value ≤ 0.05 was considered significant.

Results:

A total of 100 patients were recruited for study. These were randomly distributed into two groups of 50 patients in each group, A & B.

In A-group age range was 18 years to 35 years. Mean age was 26.04 years+4.69SD, while in B-group age range was 19 years to 35 years. Mean age was 25.70 years+4.10SD. There was no significant difference of age in two groups with p value= 0.612

LH/FSH ratio wise comparison shows that Group A have average LH/FSH ratio of 2.00+0.899SD while in Group B, it was 1.90+0.48SD observed which  was statistically insignificant with p-value = 0.718

Conclusion:

Both the therapy have shown insignificance results in term of LH/FSH Ratio in patients with Polycystic ovarian syndrome.